DOCSLIB.ORG

Summer Is Near and Skin Issues Are Here

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summer Is Near and Skin Issues Are Here 3/16/2021 DISCLOSURES • I have no disclosures • Off-label use of medications will be clearly labeled SUMMER IS NEAR AND SKIN ISSUES ARE HERE TANDY S. REPASS, MD 1 2 CLINICAL IMAGES CLINICAL IMAGES • DermNet New Zealand • www.dermnetnz.org • Unmodified images • https://creativecommons.org/licenses/by-nc-nd/3.0/nz/legalcode • Bolognia 3rd Edition • Edwards L. Genital Dermatology Atlas. Philadelphia: Lippincott Williams & Wilkins; 2004. 3 4 OBJECTIVES OBJECTIVES • Explore evidence-based practices related to • Explore evidence-based practices related to management of contact dermatitis, insect and management of contact dermatitis, insect and animal bites, and insect stings. animal bites, and insect stings. • Formulate effective strategies for managing • Formulate effective strategies for managing sunburns, burns, abrasions, abscesses, and fungal sunburns, burns, abrasions, abscesses, and fungal infections. infections. • Analyze management strategies for lacerations • Analyze management strategies for lacerations (suturing, Dermabond, medications, and follow-up). (suturing, Dermabond, medications, and follow-up). 5 6 1 3/16/2021 MANAGEMENT MANAGEMENT • Contact dermatitis • Contact dermatitis • Insect and animal bites • Insect and animal bites • Insect stings • Insect stings 7 8 CONTACT DERMATITIS CONTACT DERMATITIS • Irritant vs. allergic contact dermatitis • Irritant vs. allergic contact dermatitis • Allergic contact dermatitis • Allergic contact dermatitis • Poison ivy (urushiol) • Poison ivy (urushiol) • Nickel (chronic vs. acute) • Nickel (chronic vs. acute) • Balsam of Peru • Balsam of Peru • Neomycin • Neomycin • Formaldehyde • Formaldehyde • Special types of allergic contact dermatitis • Special types of allergic contact dermatitis • Photoallergic contact dermatitis • Photoallergic contact dermatitis • Airborne allergic contact dermatitis • Airborne allergic contact dermatitis • Stasis dermatitis • Stasis dermatitis • Hand dermatitis • Hand dermatitis • Management • Management 9 10 IRRITANT VS. ALLERGIC CONTACT IRRITANT CONTACT DERMATITIS DERMATITIS • Irritant contact dermatitis • Hand dermatitis • Non-immune-modulated • Note finger web spaces • Skin injury, direct cytotoxic effects, or cutaneous • Often from occupational exposures inflammation from contact with an irritant • Chemical irritants (solvents and cutting fluids) account for most cases • Allergic contact dermatitis • Type IV, T-cell mediated, delayed hypersensitivity response • Occurs with re-exposure • Common examples: Poison ivy, nickel, and fragrances Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010;82(3):249-55. 11 12 2 3/16/2021 IRRITANT CONTACT DERMATITIS CONTACT DERMATITIS • Lip licker’s dermatitis • Irritant diaper dermatitis • Allergic contact dermatitis • Irritant contact dermatitis • Wipes, lidocaine, male condoms, • Over-washing • Excessive lip licking spermicide, soap Edwards. Genital Dermatology Atlas. 2004 13 14 ALLERGIC CONTACT DERMATITIS CONTACT DERMATITIS • Eyelid dermatitis • Lip dermatitis • Irritant vs. allergic contact dermatitis • Allergic contact dermatitis • Poison ivy (urushiol) • Nickel (chronic vs. acute) • Balsam of Peru • Neomycin • Formaldehyde • Special types of allergic contact dermatitis • Photoallergic contact dermatitis • Airborne allergic contact dermatitis • Stasis dermatitis • Hand dermatitis • Management 15 16 URUSHIOL POISON IVY DERMATITIS • Sap of rhus plants • Wash off immediately before it is absorbed • Poison ivy, oak, and sumac • 50% can be removed at 10 minutes, 25% at 15 • Plants brush across skin minutes, and 10% at 30 minutes causing linear streaks of • After 30 minutes, sufficient penetration of urushiol erythema and vesicles has occurred • Lack of definitive preventative therapy besides avoidance Kim Y, Flamm A, ElSohly MA, Kaplan DH, Hage RJ Jr, Hamann CP, Usatine RP, Riojas M. Diagnosis and management of contact Kim Y, Flamm A, ElSohly MA, Kaplan DH, Hage RJ Jr, Hamann CP, Marks JG Jr. Poison Ivy, Oak, and Sumac Dermatitis: What is Marks JG Jr. Poison Ivy, Oak, and Sumac Dermatitis: What is dermatitis. Am Fam Physician 2010;82(3):249-55. Known and What is New? Dermatitis 2019;30(3): 183-190. Known and What is New? Dermatitis 2019;30(3): 183-190. 17 18 3 3/16/2021 NICKEL DERMATITIS NICKEL DERMATITIS • Component of many metals • White gold, German silver, gold plating, solder, stainless steel • Hairdressers using nickel- containing scissors • Crochet hooks Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010;82(3):249-55. Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010;82(3):249-55. 19 20 ALLERGIC CONTACT DERMATITIS: NICKEL DERMATITIS: CHRONIC ACUTE Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010;82(3):249-55. Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010;82(3):249-55. 21 22 BALSAM OF PERU NEOMYCIN • In personal care products and cosmetics • Over-the-counter • Fragrance topical antibiotic • Fragrance masker in products labeled “unscented” • Balsam of Peru diet • Vesicles • Avoid: Spices, ketchup, chili sauce, barbecue sauce, citrus products, colas, beers, wines, bakery items, candy, ice cream, chocolate, and tomatoes • Geometric • Improve systemic contact dermatitis in patients with contact allergy • Important to distinguish from infection Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010;82(3):249-55. 23 24 4 3/16/2021 NEOMYCIN FORMALDEHYDE SENSITIVITY • Diffuse truncal rash • Permanent press/wrinkle-resistant fabrics release formaldehyde • Formaldehyde in the clothing could be contributing Mowad CM, Anderson B, Scheinman P, Pootongkam S, Nedorost S, Brod B. Allergic contact dermatitis: Patient management and education. J Am Acad Dermtol. 2016;24(6): 1043-54. Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010;82(3):249-55. 25 26 SPECIAL TYPES OF ALLERGIC CONTACT CONTACT DERMATITIS DERMATITIS • Irritant vs. allergic contact dermatitis • Photoallergic contact dermatitis • Allergic contact dermatitis • Airborne contact dermatitis • Poison ivy (urushiol) • Stasis dermatitis • Nickel (chronic vs. acute) • Balsam of Peru • Hand dermatitis • Neomycin • Formaldehyde • Special types of allergic contact dermatitis • Photoallergic contact dermatitis • Airborne allergic contact dermatitis • Stasis dermatitis • Hand dermatitis • Management 27 28 PHOTOALLERGIC CONTACT AIRBORNE CONTACT DERMATITIS DERMATITIS • Sun-exposed areas • Sparing behind the ear, under • Allergic contact dermatitis the chin, and under clothing • Irritant contact dermatitis • Areas on the skin with maximal exposure to sunlight • Most common causative • Type IV hypersensitivity agent is plants • Requires chemical exposed to Bolognia. Dermatology. 3rd ed. 2012. UV radiation • Photopatch testing Chrysanthemum allergy • Sunscreens (most frequently) Mowad CM, Anderson B, Scheinman P, Pootongkam S, Nedorost S, Brod B. Allergic contact dermatitis: Patient management and education. J Am Acad Dermtol. 2016;24(6): 1043-54. 29 30 5 3/16/2021 STASIS DERMATITIS CHRONIC HAND ECZEMA • Irritant contact dermatitis • Avoid latex gloves • Wound secretions • Wear nonlatex gloves • Allergic contact dermatitis when working with from various topicals solvents, soaps, and • Topical antibiotics detergents • Lanolin derivatives • Use cotton liners under • Fragrances gloves • Preservatives • Contact sensitization leads to secondary dissemination • Note the eruption on the arms • Id Reaction Bolognia. Dermatology. 3rd ed. 2012. Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010;82(3):249-55. 31 32 CHRONIC HAND ECZEMA CONTACT DERMATITIS • Patch testing positive to • Irritant vs. allergic contact dermatitis potassium dichromate • Allergic contact dermatitis and a piece of his glove • Poison ivy (urushiol) • Nickel (chronic vs. acute) • Balsam of Peru • Neomycin • Formaldehyde • Special types of allergic contact dermatitis • Photoallergic contact dermatitis • Airborne allergic contact dermatitis • Stasis dermatitis • Hand dermatitis • Management Bolognia. Dermatology. 3rd ed. 2012. 33 34 MANAGEMENT CONTACT DERMATITIS: MANAGEMENT • Education • Identify and avoid causative • Self-management substance • Education • Topical treatment • Self-management • Dimethylglyoxime test (nickel • Systemic treatment spot test) for nickel allergy • Widely available online • Patch testing/TRUE Test • Pink color change indicates presence of nickel • Example: Nickel Dermatitis • Cover metal tabs on jeans with iron-on patches or coats of clear nail polish Bolognia. Dermatology. 3rd ed. 2012. 35 36 6 3/16/2021 EDUCATION SELF-MANAGEMENT • Education on reading labels • Advise on how to test a new skin care product • “Fragrance-free” • Repeat Open Application Test • “Sensitive skin” • Apply a small amount of product to the volar aspect of the • “Dermatologist-tested” forearm twice a day for 1-2 weeks • “For baby” • If any eczematous reaction occurs they should avoid the • These products can still contain fragrance product • If ingredients are not used ”solely to impart an odor to a product” it is legal for a “fragrance-free” product to contain a fragrance Mowad CM, Anderson B, Scheinman P, Pootongkam S, Nedorost S, Brod B. Allergic contact dermatitis: Patient management and education. J Am Acad Dermtol. 2016;24(6): 1043-54. Rashid RS, Shim TN. Contact dermatitis. BMJ
Load more

Recommended publications
  • New Insights Into the Effect of Amorolfine Nail Lacquer
    Review article New insights into the effect of amorolfine nail lacquer C. Flagothier, C. Pie´ rard-Franchimont and G. E. Pie´ rard Department of Dermatopathology, University Hospital of Lie`ge, Lie`ge, Belgium Summary Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains uncertain. Several factors account for treatment failure, of which the pharmacokinetics and pharmacodynamics of the antifungal are of importance. The taxonomic nature and ungual location of the fungus cannot be neglected, besides the type of nail and its growth rate. In addition, the biological cycle of the fungus and the metabolic activity of the pathogen likely play a marked influence in drug response. The presence of natural antimicrobial peptides in the nail is also probably a key feature controlling the cure rates. There are many outstanding publications that cover the full spectrum of the field. The purpose of this review is to put in perspective some facets of activity of the topical treatment using amorolfine nail laquer. The antifungal activity of the drug is likely less pronounced in onychomycosis than that expected from conventional in vitro studies. However, the nail laquer formulation should reduce the propensity to form antifungal-resistant spores and limit the risk of reinfection. Key words: amorolfine, antifungal, fungus, onychomycosis, spore. Topical treatments are often considered to be less Introduction efficacious than current oral treatments. However, some During the last 2 decades, the efficacy of treating topical formulations may provide effects that cannot be onychomycoses has been considerably improved by achieved by other treatments. In discussing the treat- the introduction of new generations of potent antifun- ment of onychomycosis, it should not be forgotten that gals.
    [Show full text]
  • Evaluation of the Efficacy and Safety of Tavaborole Topical Solution, 5%, In
    Journal of Dermatological Treatment ISSN: 0954-6634 (Print) 1471-1753 (Online) Journal homepage: http://www.tandfonline.com/loi/ijdt20 Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies Aditya K. Gupta, Steve Hall, Lee T. Zane, Shari R. Lipner & Phoebe Rich To cite this article: Aditya K. Gupta, Steve Hall, Lee T. Zane, Shari R. Lipner & Phoebe Rich (2017): Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies, Journal of Dermatological Treatment, DOI: 10.1080/09546634.2017.1329510 To link to this article: http://dx.doi.org/10.1080/09546634.2017.1329510 Accepted author version posted online: 18 May 2017. Published online: 30 May 2017. Submit your article to this journal Article views: 41 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ijdt20 Download by: [Oregon Health & Science University Library] Date: 27 September 2017, At: 13:42 JOURNAL OF DERMATOLOGICAL TREATMENT, 2017 https://doi.org/10.1080/09546634.2017.1329510 ORIGINAL ARTICLE Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies Aditya K.
    [Show full text]
  • Pompholyx Factsheet Pompholyx Eczema (Also Known As Dyshidrotic Eczema/Dermatitis) Is a Type of Eczema That Usually Affects the Hands and Feet
    12 Pompholyx factsheet Pompholyx eczema (also known as dyshidrotic eczema/dermatitis) is a type of eczema that usually affects the hands and feet. In most cases, pompholyx eczema involves the development of intensely itchy, watery blisters, mostly affecting the sides of the fingers, the palms of the hands and soles of the feet. Some people have pompholyx eczema on their hands and/or feet with other types of eczema elsewhere on the body. This condition can occur at any age but is usually seen in adults under 40, and is more common in women. The skin is initially very itchy with a burning sensation of heat and prickling in the palms and/or soles. Then comes a sudden crop of small blisters (vesicles), which turn into bigger weepy blisters, which can become infected, causing redness, pain, swelling and pustules. There is often subsequent peeling as the skin dries out, and then the skin can become red and dry with painful cracks (skin fissures). Pompholyx eczema can also affect the nail folds and skin around the nails, causing swelling (paronychia). What causes it? A reaction could be the result of contact with potential irritants such as soap, detergents, solvents, acids/alkalis, The exact causes of pompholyx eczema are not known, chemicals and soil, causing irritant contact dermatitis. Or although it is thought that factors such as stress, there could be an allergic reaction to a substance that is sensitivity to metal compounds (such as nickel, cobalt or not commonly regarded as an irritant, such as rubber or chromate), heat and sweating can aggravate this nickel, causing allergic contact dermatitis.
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • HMSA ASO Topical Antifungals Jublia (Efinaconazole) Kerydin (Tavaborole
    PA Request Criteria HMSA ASO Topical Antifungals This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 855-762-5207. Please contact CVS/Caremark at 855-240-0543 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Topical Antifungals. Patient Information Patient Name: Patient Phone: - - Patient ID: Patient Group No: Patient DOB: / / Prescribing Physician Physician Name: Physician - - Phone: Physician Fax: - - Physician Address: City, State, Zip: Drug Name (select from list of drugs shown) Jublia (efinaconazole) Kerydin (tavaborole) Oxiconazole Cream Oxistat Cream (oxiconazole) Quantity: ____________ Frequency: __________________ Strength: __________________ Route of Administration: _______________________ Expected Length of Therapy: _____________________ Diagnosis: ICD Code: __________________________________ Comments: _____________________________________________________ ______________________________________________________________________ ______________________________________________________________________ Please check the appropriate answer for each applicable question. 1. Is this a request for oxiconazole cream (Oxistat)? Y N 2. Is the requested drug being prescribed for any of the following: A) tinea corporis, B) tinea Y N cruris, C) tinea pedis, D) tinea versicolor? 3. Is the drug being prescribed for onychomycosis of the toenail(s) due to Trichophyton Y N rubrum and Trichophyton mentagrophytes? 4. Has the diagnosis been confirmed with a fungal diagnostic test (e.g., KOH preparation, Y N fungal culture, or nail biopsy)? I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.
    [Show full text]
  • Hand Dermatitis – Contact Dermatitis David E
    3/2/2021 Hand Dermatitis – Contact Dermatitis David E. Cohen, M.D., M.P.H. Charles and Dorothea Harris Professor and Vice Chairman for Clinical Affairs Director of Allergic, Occupational and Environmental Dermatology New York University School of Medicine Department of Dermatology IEC 2021 Hand Eczema Virtual Symposium 1 •David E Cohen has declared the following financial interests: . Consultant and Honorarium: . Ferndale Laboratories, . Asana . Medimetriks . Leo . UCB . Cutanea [past] . Ferrer [past] . Celgene [past] . Novartis . Dermavant . FSJ . FIDE. (FIDE receives industry sponsorship from AbbVie, Almirall, Amgen, Bausch and Lomb, Bristol- Myers Squibb, Celgene Dermavant, Dermira, Janssen, Kyowa Hakko Kirin, LEO, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Sun Pharma, UCB, Valeant) . Cosmetic Ingredient Review (CIR) •Stock or stock options: Dermira [past], Medimetriks [past], Brickell Biotech, Kadmon, Evommune, Timber •Board of Directors: Kadmon, Timber, Evommune, [Dermira-Past] I will discuss non-FDA approved patch test allergens, and emerging therapies 2 Hand Dermatitis • General population prevalence is 5% to 10% . Health care workers, exposed to wet work, frequent hand washing, and AD. Atopic dermatitis (AD) is recognized as the top risk factor Causes: • Exogenous: Irritant and Allergic Contact Dermatitis • Endogenous: Psoriasis, Dyshidrosis, Atopic Dermatitis, Nummular • ID • HYBRID • Spectrum for eczematous disease is vesicular and eroded to hyperkeratotic and fissured • Hand Psoriasis may have higher rates of allergic contact dermatitis. Int J Occup Environ Health. 2018 Jan 23:1-10. Ther Clin Risk Manag. 2020 Dec 31;16:1319-1332. doi: Contact Dermatitis. 2014 Jan;70(1):44-55. 10.2147/TCRM.S292504.eCollection 2020 Indian Dermatol Online J. 2012 Sep;3(3):177-81.
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Common Derm Conditions and Treatments
    4/10/17 Classes of Dermatologic Medications What is that?! Common Dermatologic Conditions and ● Topical Immune Suppressants ● Immune Suppressants How to Treat Them ● Vitamin D Derivatives ● Antibiotics, Antivirals, Antiparasitic Matthew Fox, MD ● Retinoids ● Antimalarials Assistant Professor, Division of Dermatology ● Biologic Agents Dell Medical School, University of Texas at Austin Director of Dermatologic Surgery, Seton Healthcare Family ● Chemotherapeutic agents Learning Objectives Approach to Dermatologic Conditions • Know the clinical subtypes of acne *Know the mechanism and recommended dosing of topical retinoids, oral antibiotics and oral retinoids in the management of acne Acne • Understand the clinical presentation cutaneous dermatophyte infection Infectious diseases of the Skin *Know the classes and recommended dosing of antifungal treatments • Recognize the clinical manifestations of dermatitis Eczema *Know the relative potencies, side effects and indications of topical steroids Psoriasis • Describe the classic clinical findings for psoriasis *Know the mechanism of action and side effects of systemic antipsoriatic medications Sun Damage / Actinic Keratoses • Know the pertinent history and physical exam findings associated with a diagnosis of skin cancer, including the ABCDEs of melanoma Fundamentals Words to the wise… • All medications have side effects If you advise the patients of side effects ahead of time, you are informing the • Always consider drug interactions, patient. including with food and supplements If you did not tell the patient about a known • Always consider pregnancy and lactation side effect until after they experience status that side effect, it is an excuse 1 4/10/17 Reference: Approach to Dermatologic Conditions • Wolverton SE, ed. Acne Comprehensive Infectious diseases of the Skin Dermatologic Drug Eczema nd Therapy, 2 Ed.
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Federal Register/Vol. 83, No. 31/Wednesday, February 14, 2018
    Federal Register / Vol. 83, No. 31 / Wednesday, February 14, 2018 / Notices 6563 Wireless Telecommunications Bureau Signed: DEPARTMENT OF HEALTH AND and Wireline Competition Bureau (the Dayna C. Brown, HUMAN SERVICES Bureaus) may implement, and (3) certify Secretary and Clerk of the Commission. Centers for Disease Control and its challenge. The USAC system will [FR Doc. 2018–03166 Filed 2–12–18; 4:15 pm] validate a challenger’s evidence using Prevention BILLING CODE 6715–01–P an automated challenge validation [CDC–2018–0004; NIOSH–233–B] process. Once all valid challenges have been identified, a challenged party that NIOSH List of Antineoplastic and Other chooses to respond to any valid FEDERAL RESERVE SYSTEM Hazardous Drugs in Healthcare challenge(s) may submit additional data Settings: Proposed Additions to the via the online USAC portal during the Change in Bank Control Notices; NIOSH Hazardous Drug List 2018 established response window. A Acquisitions of Shares of a Bank or AGENCY: Centers for Disease Control and challenged party may submit technical Bank Holding Company information that is probative regarding Prevention, HHS. ACTION: Notice of draft document the validity of a challenger’s speed tests, The notificants listed below have available for public comment. including speed test data and other applied under the Change in Bank device-specific data collected from Control Act (12 U.S.C. 1817(j)) and transmitter monitoring software or, SUMMARY: The National Institute for § 225.41 of the Board’s Regulation Y (12 alternatively, may submit its own speed Occupational Safety and Health test data that conforms to the same CFR 225.41) to acquire shares of a bank (NIOSH) of the Centers for Disease standards and requirements specified by or bank holding company.
    [Show full text]
  • Oral Antifungals Month/Year of Review: July 2015 Date of Last
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update with New Drug Evaluation: Oral Antifungals Month/Year of Review: July 2015 Date of Last Review: March 2013 New Drug: isavuconazole (a.k.a. isavunconazonium sulfate) Brand Name (Manufacturer): Cresemba™ (Astellas Pharma US, Inc.) Current Status of PDL Class: See Appendix 1. Dossier Received: Yes1 Research Questions: Is there any new evidence of effectiveness or safety for oral antifungals since the last review that would change current PDL or prior authorization recommendations? Is there evidence of superior clinical cure rates or morbidity rates for invasive aspergillosis and invasive mucormycosis for isavuconazole over currently available oral antifungals? Is there evidence of superior safety or tolerability of isavuconazole over currently available oral antifungals? • Is there evidence of superior effectiveness or safety of isavuconazole for invasive aspergillosis and invasive mucormycosis in specific subpopulations? Conclusions: There is low level evidence that griseofulvin has lower mycological cure rates and higher relapse rates than terbinafine and itraconazole for adult 1 onychomycosis.2 There is high level evidence that terbinafine has more complete cure rates than itraconazole (55% vs. 26%) for adult onychomycosis caused by dermatophyte with similar discontinuation rates for both drugs.2 There is low
    [Show full text]